Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis

Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug metabolism and disposition 2018-04, Vol.46 (4), p.429-439
Hauptverfasser: Liu, Hong, Stresser, David M., Michmerhuizen, Melissa J., Li, Xiaofeng, Othman, Ahmed A., Reed, Aimee D., Schrimpf, Michael R., Sydor, Jens, Lee, Anthony J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 439
container_issue 4
container_start_page 429
container_title Drug metabolism and disposition
container_volume 46
creator Liu, Hong
Stresser, David M.
Michmerhuizen, Melissa J.
Li, Xiaofeng
Othman, Ahmed A.
Reed, Aimee D.
Schrimpf, Michael R.
Sydor, Jens
Lee, Anthony J.
description Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and 12.4% (±9.3%) in feces. Metabolite profiling indicated that ABT-126 had been extensively metabolized, with 6.6% of the dose remaining as unchanged parent drug in urine. Parent drug accounted for 12.2% of the administered radioactivity in feces. The primary metabolic transformations of ABT-126 involved aza-adamantane N-oxidation (M1, 50.3% in urine) and aza-adamantane N-glucuronidation (M11, 19.9% in urine). M1 and M11 were also major circulating metabolites, accounting for 32.6% and 36.6% of the drug-related material in plasma, respectively. These results demonstrated that ABT-126 is eliminated primarily by hepatic metabolism, followed by urinary excretion. Enzymatic studies suggested that M1 formation is mediated primarily by human liver flavin-containing monooxygenase (FMO)3 and, to a lesser extent, by human kidney FMO1; M11 is generated mainly by human uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A4, whereas UGT 2B10 also contributes to ABT-126 glucuronidation. Species-dependent formation of M11 was observed in hepatocytes; M11 was formed in human and monkey hepatocytes, but not in rat and dog hepatocytes, suggesting that monkeys constitute an appropriate model for predicting the fate of compounds undergoing significant N-glucuronidation. M1 and M11 are not expected to have clinically relevant on- or off-target pharmacologic activities. In summary, this study characterized ABT-126 metabolites in the circulation and excreta and the primary elimination pathways of ABT-126 in humans.
doi_str_mv 10.1124/dmd.117.077511
format Article
fullrecord <record><control><sourceid>proquest_elsev</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989606649</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090955624054370</els_id><sourcerecordid>2031736316</sourcerecordid><originalsourceid>FETCH-LOGICAL-e2201-13b505b9650917328cad326b7de12e127130dbe9b41535188afae82b11a8469d3</originalsourceid><addsrcrecordid>eNpdks1uEzEUhUcIJEJhy9oSGzZTfO35M7t0SlukpqCSSuxGHs-dxJFjp7YnIrwVL8LD8AQ4BDZIlu5ZfNfnyD5Z9hroOQAr3g3bIYn6nNZ1CfAkm0HJIKdUfH2azdKguSjL6nn2IoQNpVAUXMyyXwuMsndGhy2RdiCXOuxc0FE7S9xIJLlzezTkCxpUUe-R_PxRkzucvLPSkLnCeDBqnfYtkntUuIvOk_nKWR0imV8sc2AV0ZbcTFtpw3vSrqWXKqLX3-U_k7hGspCbtHjvDAYyJnVl5F7bvHU2Sm21XZGFs859O6zQypCgY9iHy8_5tZnUMY0LB0OWPpmM6BNBYF78gdgF0GOCVkZpDkGHl9mzUZqAr_7Os-zh6sOyvclvP11_bOe3OTJGIQfel7TsRVVSATVnjZIDZ1VfDwgsnRo4HXoUfQElL6Fp5CixYT2AbIpKDPwse3u6d-fd44QhdlsdFBojLbopdCAaUdGqKkRC3_yHbtzk0wuHjlGe3CsOVaKaE4Up9V6j74LSaBUO2qff6QanO6DdsQxdKkMSdXcqA_8Nu6KqpQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2031736316</pqid></control><display><type>article</type><title>Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Liu, Hong ; Stresser, David M. ; Michmerhuizen, Melissa J. ; Li, Xiaofeng ; Othman, Ahmed A. ; Reed, Aimee D. ; Schrimpf, Michael R. ; Sydor, Jens ; Lee, Anthony J.</creator><creatorcontrib>Liu, Hong ; Stresser, David M. ; Michmerhuizen, Melissa J. ; Li, Xiaofeng ; Othman, Ahmed A. ; Reed, Aimee D. ; Schrimpf, Michael R. ; Sydor, Jens ; Lee, Anthony J.</creatorcontrib><description>Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and 12.4% (±9.3%) in feces. Metabolite profiling indicated that ABT-126 had been extensively metabolized, with 6.6% of the dose remaining as unchanged parent drug in urine. Parent drug accounted for 12.2% of the administered radioactivity in feces. The primary metabolic transformations of ABT-126 involved aza-adamantane N-oxidation (M1, 50.3% in urine) and aza-adamantane N-glucuronidation (M11, 19.9% in urine). M1 and M11 were also major circulating metabolites, accounting for 32.6% and 36.6% of the drug-related material in plasma, respectively. These results demonstrated that ABT-126 is eliminated primarily by hepatic metabolism, followed by urinary excretion. Enzymatic studies suggested that M1 formation is mediated primarily by human liver flavin-containing monooxygenase (FMO)3 and, to a lesser extent, by human kidney FMO1; M11 is generated mainly by human uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A4, whereas UGT 2B10 also contributes to ABT-126 glucuronidation. Species-dependent formation of M11 was observed in hepatocytes; M11 was formed in human and monkey hepatocytes, but not in rat and dog hepatocytes, suggesting that monkeys constitute an appropriate model for predicting the fate of compounds undergoing significant N-glucuronidation. M1 and M11 are not expected to have clinically relevant on- or off-target pharmacologic activities. In summary, this study characterized ABT-126 metabolites in the circulation and excreta and the primary elimination pathways of ABT-126 in humans.</description><identifier>ISSN: 0090-9556</identifier><identifier>EISSN: 1521-009X</identifier><identifier>DOI: 10.1124/dmd.117.077511</identifier><language>eng</language><publisher>Bethesda: Elsevier Inc</publisher><subject>Catalysis ; Dimethylaniline monooxygenase (N-oxide-forming) ; Drug dosages ; Excretion ; Feces ; Flavin ; Glucuronosyltransferase ; Hepatocytes ; Kidneys ; Liver ; Metabolism ; Metabolites ; Monkeys ; Oxidation ; Pharmacology ; Radioactivity ; Uridine ; Urine</subject><ispartof>Drug metabolism and disposition, 2018-04, Vol.46 (4), p.429-439</ispartof><rights>2018 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright Lippincott Williams &amp; Wilkins Ovid Technologies Apr 1, 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Stresser, David M.</creatorcontrib><creatorcontrib>Michmerhuizen, Melissa J.</creatorcontrib><creatorcontrib>Li, Xiaofeng</creatorcontrib><creatorcontrib>Othman, Ahmed A.</creatorcontrib><creatorcontrib>Reed, Aimee D.</creatorcontrib><creatorcontrib>Schrimpf, Michael R.</creatorcontrib><creatorcontrib>Sydor, Jens</creatorcontrib><creatorcontrib>Lee, Anthony J.</creatorcontrib><title>Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis</title><title>Drug metabolism and disposition</title><description>Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and 12.4% (±9.3%) in feces. Metabolite profiling indicated that ABT-126 had been extensively metabolized, with 6.6% of the dose remaining as unchanged parent drug in urine. Parent drug accounted for 12.2% of the administered radioactivity in feces. The primary metabolic transformations of ABT-126 involved aza-adamantane N-oxidation (M1, 50.3% in urine) and aza-adamantane N-glucuronidation (M11, 19.9% in urine). M1 and M11 were also major circulating metabolites, accounting for 32.6% and 36.6% of the drug-related material in plasma, respectively. These results demonstrated that ABT-126 is eliminated primarily by hepatic metabolism, followed by urinary excretion. Enzymatic studies suggested that M1 formation is mediated primarily by human liver flavin-containing monooxygenase (FMO)3 and, to a lesser extent, by human kidney FMO1; M11 is generated mainly by human uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A4, whereas UGT 2B10 also contributes to ABT-126 glucuronidation. Species-dependent formation of M11 was observed in hepatocytes; M11 was formed in human and monkey hepatocytes, but not in rat and dog hepatocytes, suggesting that monkeys constitute an appropriate model for predicting the fate of compounds undergoing significant N-glucuronidation. M1 and M11 are not expected to have clinically relevant on- or off-target pharmacologic activities. In summary, this study characterized ABT-126 metabolites in the circulation and excreta and the primary elimination pathways of ABT-126 in humans.</description><subject>Catalysis</subject><subject>Dimethylaniline monooxygenase (N-oxide-forming)</subject><subject>Drug dosages</subject><subject>Excretion</subject><subject>Feces</subject><subject>Flavin</subject><subject>Glucuronosyltransferase</subject><subject>Hepatocytes</subject><subject>Kidneys</subject><subject>Liver</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Monkeys</subject><subject>Oxidation</subject><subject>Pharmacology</subject><subject>Radioactivity</subject><subject>Uridine</subject><subject>Urine</subject><issn>0090-9556</issn><issn>1521-009X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdks1uEzEUhUcIJEJhy9oSGzZTfO35M7t0SlukpqCSSuxGHs-dxJFjp7YnIrwVL8LD8AQ4BDZIlu5ZfNfnyD5Z9hroOQAr3g3bIYn6nNZ1CfAkm0HJIKdUfH2azdKguSjL6nn2IoQNpVAUXMyyXwuMsndGhy2RdiCXOuxc0FE7S9xIJLlzezTkCxpUUe-R_PxRkzucvLPSkLnCeDBqnfYtkntUuIvOk_nKWR0imV8sc2AV0ZbcTFtpw3vSrqWXKqLX3-U_k7hGspCbtHjvDAYyJnVl5F7bvHU2Sm21XZGFs859O6zQypCgY9iHy8_5tZnUMY0LB0OWPpmM6BNBYF78gdgF0GOCVkZpDkGHl9mzUZqAr_7Os-zh6sOyvclvP11_bOe3OTJGIQfel7TsRVVSATVnjZIDZ1VfDwgsnRo4HXoUfQElL6Fp5CixYT2AbIpKDPwse3u6d-fd44QhdlsdFBojLbopdCAaUdGqKkRC3_yHbtzk0wuHjlGe3CsOVaKaE4Up9V6j74LSaBUO2qff6QanO6DdsQxdKkMSdXcqA_8Nu6KqpQ</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Liu, Hong</creator><creator>Stresser, David M.</creator><creator>Michmerhuizen, Melissa J.</creator><creator>Li, Xiaofeng</creator><creator>Othman, Ahmed A.</creator><creator>Reed, Aimee D.</creator><creator>Schrimpf, Michael R.</creator><creator>Sydor, Jens</creator><creator>Lee, Anthony J.</creator><general>Elsevier Inc</general><general>American Society for Pharmacology and Experimental Therapeutics, Inc</general><scope>7QO</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201804</creationdate><title>Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis</title><author>Liu, Hong ; Stresser, David M. ; Michmerhuizen, Melissa J. ; Li, Xiaofeng ; Othman, Ahmed A. ; Reed, Aimee D. ; Schrimpf, Michael R. ; Sydor, Jens ; Lee, Anthony J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e2201-13b505b9650917328cad326b7de12e127130dbe9b41535188afae82b11a8469d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Catalysis</topic><topic>Dimethylaniline monooxygenase (N-oxide-forming)</topic><topic>Drug dosages</topic><topic>Excretion</topic><topic>Feces</topic><topic>Flavin</topic><topic>Glucuronosyltransferase</topic><topic>Hepatocytes</topic><topic>Kidneys</topic><topic>Liver</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Monkeys</topic><topic>Oxidation</topic><topic>Pharmacology</topic><topic>Radioactivity</topic><topic>Uridine</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Hong</creatorcontrib><creatorcontrib>Stresser, David M.</creatorcontrib><creatorcontrib>Michmerhuizen, Melissa J.</creatorcontrib><creatorcontrib>Li, Xiaofeng</creatorcontrib><creatorcontrib>Othman, Ahmed A.</creatorcontrib><creatorcontrib>Reed, Aimee D.</creatorcontrib><creatorcontrib>Schrimpf, Michael R.</creatorcontrib><creatorcontrib>Sydor, Jens</creatorcontrib><creatorcontrib>Lee, Anthony J.</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Drug metabolism and disposition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Hong</au><au>Stresser, David M.</au><au>Michmerhuizen, Melissa J.</au><au>Li, Xiaofeng</au><au>Othman, Ahmed A.</au><au>Reed, Aimee D.</au><au>Schrimpf, Michael R.</au><au>Sydor, Jens</au><au>Lee, Anthony J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis</atitle><jtitle>Drug metabolism and disposition</jtitle><date>2018-04</date><risdate>2018</risdate><volume>46</volume><issue>4</issue><spage>429</spage><epage>439</epage><pages>429-439</pages><issn>0090-9556</issn><eissn>1521-009X</eissn><abstract>Mass balance, metabolism, and excretion of ABT-126, an α7 neuronal acetylcholine receptor agonist, were characterized in healthy male subjects (n = 4) after a single 100-mg (100 μCi) oral dose. The total recovery of the administered radioactivity was 94.0% (±2.09%), with 81.5% (±10.2%) in urine and 12.4% (±9.3%) in feces. Metabolite profiling indicated that ABT-126 had been extensively metabolized, with 6.6% of the dose remaining as unchanged parent drug in urine. Parent drug accounted for 12.2% of the administered radioactivity in feces. The primary metabolic transformations of ABT-126 involved aza-adamantane N-oxidation (M1, 50.3% in urine) and aza-adamantane N-glucuronidation (M11, 19.9% in urine). M1 and M11 were also major circulating metabolites, accounting for 32.6% and 36.6% of the drug-related material in plasma, respectively. These results demonstrated that ABT-126 is eliminated primarily by hepatic metabolism, followed by urinary excretion. Enzymatic studies suggested that M1 formation is mediated primarily by human liver flavin-containing monooxygenase (FMO)3 and, to a lesser extent, by human kidney FMO1; M11 is generated mainly by human uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A4, whereas UGT 2B10 also contributes to ABT-126 glucuronidation. Species-dependent formation of M11 was observed in hepatocytes; M11 was formed in human and monkey hepatocytes, but not in rat and dog hepatocytes, suggesting that monkeys constitute an appropriate model for predicting the fate of compounds undergoing significant N-glucuronidation. M1 and M11 are not expected to have clinically relevant on- or off-target pharmacologic activities. In summary, this study characterized ABT-126 metabolites in the circulation and excreta and the primary elimination pathways of ABT-126 in humans.</abstract><cop>Bethesda</cop><pub>Elsevier Inc</pub><doi>10.1124/dmd.117.077511</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0090-9556
ispartof Drug metabolism and disposition, 2018-04, Vol.46 (4), p.429-439
issn 0090-9556
1521-009X
language eng
recordid cdi_proquest_miscellaneous_1989606649
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Catalysis
Dimethylaniline monooxygenase (N-oxide-forming)
Drug dosages
Excretion
Feces
Flavin
Glucuronosyltransferase
Hepatocytes
Kidneys
Liver
Metabolism
Metabolites
Monkeys
Oxidation
Pharmacology
Radioactivity
Uridine
Urine
title Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T19%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_elsev&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolism%20and%20Disposition%20of%20a%20Novel%20Selective%20%CE%B17%20Neuronal%20Acetylcholine%20Receptor%20Agonist%20ABT-126%20in%20Humans:%20Characterization%20of%20the%20Major%20Roles%20for%20Flavin-Containing%20Monooxygenases%20and%20UDP-Glucuronosyl%20Transferase%201A4%20and%202B10%20in%20Catalysis&rft.jtitle=Drug%20metabolism%20and%20disposition&rft.au=Liu,%20Hong&rft.date=2018-04&rft.volume=46&rft.issue=4&rft.spage=429&rft.epage=439&rft.pages=429-439&rft.issn=0090-9556&rft.eissn=1521-009X&rft_id=info:doi/10.1124/dmd.117.077511&rft_dat=%3Cproquest_elsev%3E2031736316%3C/proquest_elsev%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2031736316&rft_id=info:pmid/&rft_els_id=S0090955624054370&rfr_iscdi=true